ArticleTranslational cancer research2019
Clinicopathological and prognostic significance of NCALD protein expression in lung adenocarcinoma.
Article in Translational cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
- Prognostic significance of AP-2α/γ targets as cancer therapeutics.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough there are great improvements in diagnostics and treatment of non-small cell lung cancer (NSCLC), it remains the leading cause of cancer-related death globally. NSCLC can be further categorized into two common subtypes, lung squamous cell carcinoma (LUSC) and lung adenocarcinoma (LUAD). The aims of this study were to evaluate the expression of neurocalcin delta (NCALD) in LUAD patients and to evaluate the relationship between NCALD expression and clinicopathological feature as well as overall survival (OS).
methodsThe expression level of NCALD protein was assessed by immunohistochemical analysis of tissue microarrays (TMAs) which contained 90 LUAD tissues and paired adjacent normal tissues. The relationship between NCALD expression level and clinicopathological characteristics as well as OS were investigated.
resultsThe results showed that the expression level of NCALD protein in LUAD tissues was significantly down-regulated (P<0.01) and that the NCALD level was correlated with the tumor size (P<0.001), lymph node metastasis (P=0.03) and TNM stage (P=0.015). Both Kaplan-Meier survival analysis and Cox regression univariate analysis identified that NCALD expression level, lymph node metastasis, and clinical TNM stages were prognostic factors for patients' survival (P<0.05).
conclusionsOverexpression of NCALD is a significant marker for a good prognosis in patients with LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.